1. Australia Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Algorae Pharmaceuticals Limited

Algorae Pharmaceuticals Limited

LVCLF
Algorae Pharmaceuticals LimitedUS flagOther OTC
0.01
USD
- -
- -
14.39MMarket Cap
Algorae Pharmaceuticals Limited
LVCLF
(Other OTC)

Recent

price

0.01

P/E

ratio

- -

div

yld

- -

ROIC.AI

2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
FRC
- -
- -
- -
0.01
0.02
0.02
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-0.02
-0.02
-0.02
0.02
-0.01
-0.02
-0.02
-0.01
-0.01
- -
-0.01
- -
- -
- -
- -
- -
Basic EPS, GAAP
-0.03
-0.02
-0.02
-0.01
- -
- -
-0.01
-0.01
-0.01
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.02
0.02
0.02
0.04
0.03
0.01
- -
- -
0.01
0.01
- -
- -
- -
- -
- -
- -
Book Value per Share
0.02
0.02
0.02
0.04
0.04
0.02
0.01
0.01
0.01
0.01
0.01
- -
- -
- -
- -
- -
Tangible Book Value per Share
253
282
313
362
378
378
427
474
572
572
605
605
605
887
1,347
1,663
Basic Weighted Avg Shares
- -
1
- -
4
8
7
1
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
-4,187.45
-1,364.01
-5,050.78
-114.78
-15.2
-21.4
-537.56
-3,360.95
-4,556.28
-3,517.78
-42,607.46
-99,835.86
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
-6
-6
-7
6
-3
-7
-7
-3
-4
- -
-3
-1
-1
-2
-2
-2
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-3,284.06
-1,097.31
-3,849.43
153.07
-39.3
-91.68
-1,150.97
-2,575.68
-3,548.14
-308.47
-32,565.9
-30,570.36
- -
- -
- -
- -
Profit Margin (%)
2
3
4
2
4
4
5
5
7
7
4
3
1
7
6
5
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
6
6
7
14
13
8
5
6
8
7
4
3
1
4
4
3
Total Equity
- -
- -
- -
-40.32
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
60.22
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
-85.65
-128.6
-129.91
60.65
-25.24
-92.24
-268.62
-218.73
-156.33
-11.12
-198.32
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.06%
16.75%
-19.88%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
66.11%
4.47%
-0.57%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
Similar Companies
Dimerix Limited (DXB.AX)
OliX Pharmaceuticals,Inc (226950.KQ)
Caliway Biopharmaceuticals Co. L (6919.TW)
LIDDS AB (publ) (LIDDS.ST)
UnicoCell Biomed Co., Ltd. (6794.TW)
Abpro Holdings Inc (ABPWW)
Business
Algorae Pharmaceuticals Limited (ASX:1AI; OTCQB:LVCLF) is an Australia-based clinical-stage pharmaceutical company that leverages artificial intelligence for drug discovery and development to address unmet medical needs in neurodegenerative disorders, cardiovascular disease, oncology and Parkinson's disease. The company offers its proprietary AlgoraeOS artificial intelligence platform, which employs machine learning, deep learning and neural networks to analyze extensive medical databases and identify synergistic fixed-dose drug combinations and novel therapeutic targets; AI-116, a drug candidate for dementia and neurodegenerative disorders; AI-168, targeting cardiovascular conditions including hypertension; NTCELL, an encapsulated cell therapy for Parkinson's disease; and through its commercial arm AlgoraeRx, licensed generic oncology medicines, cardiovascular and metabolic therapies. Algorae Pharmaceuticals maintains operations primarily in Australia and New Zealand, with global collaborations in research and supply. Founded in 1987 and headquartered in Melbourne, the company was formerly known as Living Cell Technologies Limited. In September 2025, Algorae signed an exclusive licensing agreement with Sakar Healthcare to distribute five generic oncology medicines in Australia and New Zealand, targeting an initial A$10 million annual market and marking its first major commercial product launch. In October 2025, it entered a binding term sheet with Cadila Pharmaceuticals for two generic medicines addressing cardiovascular and metabolic disorders in the same markets, advancing toward Therapeutic Goods Administration approvals; the company also conducts oncology target validation at Peter MacCallum Cancer Centre using AlgoraeOS, with 21 novel targets and results expected in Q4 2025; and identified 24 new wholly owned AI-generated drug targets for preclinical evaluation, substantially expanding its pipeline.

Company News

APIChat